Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864942 · ClinicalTrials.gov registry record · Phase 1
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00864942 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 28 participants.
The verdict
NCT00864942, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is for subjects with a B-cell lymphoid malignancy (lymphoma) or chronic lymphocytic leukemia (CLL) that has come back after or did not get better with previous treatment. The purpose of this study is to find out the highest dose of lenalidomide that can be given together with bendamustine and rituximab. The study will also look what effects the combination of lenalidomide and bendamustine and the combination of lenalidomide, bendamustine and rituximab will have on patients and their disease.
Interventions
- DRUG bendamustine and lenalidomide
- DRUG BL-NHL
- DRUG BLR-CLL
- DRUG BLR-NHL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864942
The ClinicalTrials.gov registry entry for NCT00864942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bendamustine and lenalidomide is the first listed.
NCT00864942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864942 about?
NCT00864942 is a clinical study titled "Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)". This study is for subjects with a B-cell lymphoid malignancy (lymphoma) or chronic lymphocytic leukemia (CLL) that has come back after or did not get better with previous treatment. The purpose of this study is to find out the highest dose of lenalidomide that can be given together with bendamustine...
What is the current status of trial NCT00864942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00864942?
The interventions under investigation include: bendamustine and lenalidomide (DRUG), BL-NHL (DRUG), BLR-CLL (DRUG), BLR-NHL (DRUG).
Who is sponsoring clinical trial NCT00864942?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.